567
Participants
Start Date
November 11, 2015
Primary Completion Date
May 9, 2017
Study Completion Date
October 23, 2019
ABC/DTG/3TC
600/50/300 mg FDC tablets administered orally once daily without regard to food
B/F/TAF
50/200/25 mg FDC tablets administered orally once daily without regard to food
ABC/DTG/3TC Placebo
Tablets administered orally once daily without regard to food
B/F/TAF Placebo
Tablets administered orally once daily without regard to food
Sydney
Nice
Barcelona
Badalona
Ghent
New York
Berlin
Berlin
Córdoba
Buffalo
Santiago de Compostela
Philadelphia
Washington D.C.
Washington D.C.
Hamburg
Greenville
Madrid
Huntersville
Charlotte
Decatur
Augusta
Macon
Savannah
Pensacola
DeLand
Orlando
Vero Beach
Miami
Miami Beach
Wilton Manors
Fort Lauderdale
Fort Lauderdale
West Palm Beach
Tampa
Ft. Pierce
Louisville
Seville
Nantes
Essen
Berkley
Detroit
Bonn
Minneapolis
Frankfurt am Main
Chicago
Chicago
St Louis
Kansas City
New Orleans
Paris
Dallas
Dallas
Longview
Paris
Houston
Houston
Austin
München
Munich
Phoenix
Santa Fe
Los Angeles
Los Angeles
Los Angeles
Los Angeles
Beverly Hills
Palm Springs
San Leandro
Oakland
Oakland
Sacramento
Sacramento
Honolulu
Seattle
Spokane
Boston
Springfield
Newark
The Bronx
Cincinnati
Columbia
Sydney
Vancouver
Winnipeg
Montreal
Montreal
Montreal
Roma
San Juan
San Juan
Badalona
Brighton
Manchester
Manchester
Lead Sponsor
Gilead Sciences
INDUSTRY